INCB38579 |
| Katalog-Nr.GC65937 |
INCB38579 ist ein oral aktiver, hochgradig hirngÄngiger und selektiver Histamin-H4-Rezeptor (HH4R)-Antagonist (hH4R IC50=4,8 nM, mH4R IC50=42 nM, rH4R IC50=32 nM). INCB38579 zeigt entzÜndungshemmende Schmerzen und juckreizstillende AktivitÄten.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1246207-65-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
INCB38579 is an orally active, highly brain penetrable, and selective histamine H4 receptor (HH4R) antagonist (hH4R IC50=4.8 nM, mH4R IC50=42 nM, rH4R IC50=32 nM). INCB38579 shows anti-inflammatory pain and anti-pruritic activities[1].
INCB38579 (0.1 nM-10 μM; 1.5 h) inhibits histamine binding to the recombinant human and rodent histamine H4 receptors[1].
INCB38579 (0.1 nM-10 μM; 20 min) blocks histamine-induced migration of dendritic cells differentiated from human monocytes and mouse bone marrow cells[1].
NCB38579 (0-30 nM; 1.5 h) inhibits histamine-induced cell shape change and migration of purified human eosinophils dose-dependently[1].
Cell Viability Assay[1]
| Cell Line: | HEK293 cells |
| Concentration: | 0.1 nM-10 μM |
| Incubation Time: | 1.5 hours |
| Result: | Showed the IC50 values of 4.8, 42 and 21 nM for the human, mouse and rat histamine H4 receptors, respectively. |
Cell Viability Assay[1]
| Cell Line: | Human monocytes, mouse bone marrow cells, and human eosinophils |
| Concentration: | 0.1 nM-10 μM |
| Incubation Time: | 20 min |
| Result: | Showed IC50s of 13.2 and 77 nM for human monocytes and mouse bone marrow cells??respectively. Showed IC50 values of approximately 20-30 nM for purified human eosinophils. |
Cell Viability Assay[1]
| Cell Line: | HEK293 cells |
| Concentration: | 0-30 nM |
| Incubation Time: | 1.5 hours |
| Result: | Showed the IC50 values of 4.8, 42 and 21 nM for the human, mouse and rat histamine H4 receptors, respectively. |
INCB38579 (oral gavage; 100 mg/kg; once) inhibits histamine-mediated pruritus in mice[1].
INCB38579 (oral gavage; 100 mg/kg; once) shows antinociceptive functions in this acute model of inflammatory pain[1].
INCB38579 (oral gavage; 3, 10, 30, and 100 mg/kg; once) inhibits formalin-induced pain in rats and mice[1].
| Animal Model: | Female CD-1 mice histamine-induced pruritus[1] |
| Dosage: | 100 mg/kg |
| Administration: | Oral gavage; 100 mg/kg; once |
| Result: | Reduced the number of scratching bouts significantly (P<0.05). |
| Animal Model: | Sprague-Dawley rats injected with carrageenan[1] |
| Dosage: | 100 mg/kg |
| Administration: | Oral gavage; 100 mg/kg; once |
| Result: | Increased the paw withdrawal threshold from a baseline of 61 g to approximately 100 g, achieving approximately 60% in maximal possible effect. |
| Animal Model: | Male Sprague-Dawley rats and male ICR mice injected with formalin into the hind paws[1] |
| Dosage: | 3, 10, 30, and 100 mg/kg |
| Administration: | Oral gavage; 3, 10, 30, and 100 mg/kg; once |
| Result: | Showed a significant dose-dependent analgesic effect from 10 to 100 mg/kg in the phase 1 response and 30 to 100 mg/kg in the phase 2 response in the mouse formalin test. Observed a dose-dependent and statistically significant effect in the phase 1 response, ranging from10 to 100 mg/kg, in the rat formalin test. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *